Press releaseGlobe Newswire
Eledon Pharmaceuticals
ELDN · NASDAQ
$2.26+$0.095 (+4.40%)TodayMarket closed ·
Prev close $2.16
Latest news
- Press releaseGlobe Newswire
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
- Press releaseGlobe Newswire
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Press releasePRNewswire
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
- Press releasePRNewswire
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
- News
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
- Press releaseGlobe Newswire
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
- News
Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation
- Press releaseBusiness Wire
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
- Press releaseGlobe Newswire
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
- Press releaseGlobe Newswire
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
- Press releaseGlobe Newswire
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Press releasePRNewswire
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
- Press releaseGlobe Newswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
- News
Newcelx Announces Collaborative Research Agreement With Eledon Pharmaceuticals To Advance The NCEL-101 Program For Type 1 Diabetes
- Press releasePRNewswire
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
- Press releasePRNewswire
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsVandana Singh
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study
- NewsAvi Kapoor
Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
- Press releaseGlobe Newswire
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
- Press releaseGlobe Newswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.